Galmed Pharmaceuticals Ltd.
(NASDAQ : GLMD)

( )
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Interested in Gold Updates?
Receive the latest updates on the gold and silver markets.
100% secure: your email is never shared, and you may opt out at any time.
...
Health Technology » Pharmaceuticals Other
symbolcompany%chnglast%shortavg$volume
VRXValeant Pharmaceuticals International, Inc.
0.10%19.7014.1%$436.29m
SAGESAGE Therapeutics, Inc.
2.72%162.3210.9%$216.91m
SHPGShire PLC Sponsored ADR
2.77%151.270.4%$168.46m
PRGOPerrigo Co. Plc
2.93%86.506.6%$88.44m
MNKMallinckrodt Plc
1.08%23.3618.5%$79.35m
GWPHGW Pharmaceuticals PLC Sponsored ADR
-0.47%130.217.6%$59.41m
UTHRUnited Therapeutics Corporation
1.20%137.4114.5%$56.06m
JAZZJazz Pharmaceuticals Plc
0.02%135.532.2%$56.04m
ICPTIntercept Pharmaceuticals, Inc.
0.02%61.6222.0%$40.25m
RVNCRevance Therapeutics, Inc.
-0.31%32.0512.2%$36.88m
CTLTCatalent Inc
2.65%41.122.6%$36.60m
MDCOMedicines Company
0.18%27.3022.1%$36.53m
ADMSAdamas Pharmaceuticals, Inc.
1.56%32.5816.9%$36.42m
ENDPEndo International Plc
2.43%8.008.9%$33.43m
PTLAPortola Pharmaceuticals, Inc.
-1.12%47.027.8%$33.19m

Company Profile

Galmed Pharmaceuticals Ltd. is a clinical-stage biopharmaceutical company. It focuses on the development and commercialization of Aramchol, a novel, once-daily, oral therapy for treating liver diseases utilizing its proprietary first-in-class family of synthetic fatty-acid/bile-acid conjugates, or FABACs. The Aramchol is initially being developed for treating Non-Alcoholic Steato-hepatitis, or NASH, a chronic disease affecting a large population, for treating patients who also suffer from obesity and insulin resistance. The company was founded by Allen Baharaff and Tuvia Gilat in 2000 and is headquartered in Tel Aviv, Israel.